85 results about "Drug therapy treatment" patented technology

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

The invention provides a preparation method of a drug-loaded silicone grease ultrasonic contrast agent. The preparation method comprises fully dissolving silicone grease, polyethylene glycol phosphate derivatives and a fat-soluble anticancer drug in an organic solvent, adding water into the solution, carrying out whirling, removing the organic solvent, supplying water with a volume 3 times that of the solution into the solution, carrying out ultrasonic disintegration by an ultrasonic disintegrator, simultaneously and fast adding liquid fluorocarbon into the solution to obtain a pre-emulsion, and carrying out dialysis on the pre-emulsion in PBS for 1h to obtain a product. The preparation method has simple processes. The product has the average particle size of about 100nm and is conducive to aggregation at a tumor position by internal EPR effects. Siloxane silicone grease network distribution substantially improves structure stability and prolongs internal blood circulation time. Through HIFU, the drug-loaded silicone grease ultrasonic contrast agent release drugs at a local part of tumor tissue, drug treatment targeting is improved, HIFU treatment effects are substantially improved and HIFU-chemotherapy combined treatment is realized.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with Lennox-Gastaut syndrome (LGS) who are deemed to be treatment failures on their existing medication. In particular the use of CBD was found to provide a statistically significant reduction in both drop seizures and total seizure frequency in patients who have tried and failed anti-epileptic drugs (AEDs) or those who were currently taking AEDs but have uncontrolled seizures. Preferably the AEDs which have been shown to be treatment failures are one or more of rufinamide, lamotrigine, topiramate and/or felbamate. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention discloses a pharmaceutical composition for treating hypertension. The pharmaceutical composition consists of the following medicinal materials by weight: semen plantaginis, rhizoma alismatis, ginkgo leaf, chrysanthemum, blackberry lily, gastrodia elata, semen cassia, rhynohophylla, concha haliotidis, nacre mother of pearl, leech, seaweed, herba siegesbeckiae, root of kudzu vine, hawthorn, parasitic loranthus, feather cockscomb seed, apocynum venetum, fructus viticis, eucommia ulmoides, root bark of white mulberry, dried rehmannia root, achyranthes root, earthworm, oyster, pulp of dogwood fruit, kelp, lucid ganoderma, magnet, selfheal, corydalis amabilis and cinnamon. The pharmaceutical composition disclosed by the invention is obvious in drug treatment effect, free of side effect, does not produce drug dependence, and is low in treatment cost. And moreover, the pharmaceutical composition has certain treatment effect on hyperglycemia, high cholesterol and hyperlipidemia ropiness while being used for treating the hypertension.

The invention discloses a preparation method for drug targeting controlled release nano-particle eye drops, which pertains to the preparation methods of eye preparations. The invention firstly dissolves certain portions by weight of drug and biodegradable polymer in organic solvent so as to obtain solution A; additionally, certain portions by weight of cholesterol modified chitosan is dissolved in water, and solution B is obtained by stirring and rotating; the two are mixed and stirred till the organic solvent is fully volatilized; the drug-carrying polymer nanoparticles are obtained by centrifugal separation, water washing and drying; and then the eye drops are prepared by the general preparation method of the industry of eye drops. The eye drops which are prepared by the method of the invention can ensure the effective drug treatment concentration without the need of frequent and high-concentration drug delivery, can significantly prolong the eye surface acting time of the drug and release the drug continuously and constantly, the eye surface retention time of the drug-carrying particles of the eye drops can be up to six hours, the efficacy is improved and the side effects of the drug are reduced simultaneously.

The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.

A method for determining HTR1A gene polymorphism site gene and predicting 5-hydroxytrytamine re-ingestion inhibitor medicinal effect and its use are disclosed. It can predict therapeutical effect and acting time by polymorphism site oligonucleotide inspecting biological sample. It's safe, cheap and non-toxic and can be used for thymoleptic and medicine in treatment of sexual disorders.

The invention relates to a targeted drug delivery fumigation system and method for the gynecology department. A water inlet pipe with nozzles is fixedly mounted on the inner top wall of a fumigation box, a heating disinfection lamp is fixedly mounted on one side of the water inlet pipe, a bellows box is fixedly mounted on the portion, at the lower end of the heating and disinfection lamp, of the inner wall of the fumigation box, fans are installed in the bellows box, an opening is formed below an oblique pulling support plate, and a targeted positioning fumigation device is mounted in the portion, below the opening, of the interior of the fumigation box. A positioning targeted drug delivery connector is used for drug delivery so that a female private part can be accurately located; moreover, a universal adjustment rod is used for positioning, fixation and adjustment of the corresponding degree, and the positioning targeted drug delivery connector is provided with an upper drug outlet,a middle drug outlet and a lower drug outlet. According to a human body bionic principle, omnibearing fumigation drug therapy treatment is carried out to a precise position and peripheral positions ofthe female private part, precise targeted drug delivery is achieved, and the treatment effect is remarkable.

A portable, disposable, thermal drug dispensing apparatus and method of thermally controlling the delivery of medication therewith is provided. The apparatus provides a predetermined thermal energy over a predetermined amount of time to allow effective drug delivery regardless of the external environment. The apparatus produces exothermic or endothermic thermal energy, in a balanced and controlled environment via a chemical reaction between reactants contained as an integral part within the apparatus. The reactants are provided and automatically combined in a selective, predetermined manner within the apparatus to provide the desired thermal cycle needed to produce the desired, thermal environment for effective drug treatment.

Techniques are provided for administering combination of drug treatments to a patient. Information is analyzed pertaining to individual drug treatments from structurally or functionally defined drugs, drugs with unknown functions, and corresponding effects, wherein the information includes omic data including genes, transcripts, proteins, as well as experimental data from published documents. One or more combinations of drug treatments are identified with combined effects producing a positive result, wherein the positive result is directed to a specific aspect of patient health. The identified combination of drug treatments are administered to a patient.

The invention provides a composition with the function of relieving diarrhea and a preparing method and application thereof. The composition contains macromolecule glue and a polymer, and is suitablefor tumor-associated diarrhea, antibiotic-and-drug therapeutic diarrhea, intestinal inflammation disease diarrhea, diabetic diarrhea, irritable bowel syndrome diarrhea, persistent diarrhea, chronic diarrhea, viral or bacterial infection diarrhea, and enteral nutrition intolerance diarrhea and alternating diarrhea and constipation of critically-ill patients. The composition can be applied to patients through nasal feeding and oral administration, can be used for both children and adults, has two-way regulation effects on diarrhea and constipation, and can be taken for a long term.

The invention belongs to the technical field of medicines, and discloses application of a UPK1A-AS1 inhibitor in preparation of antitumor drugs. The invention discloses application of the UPK1A-AS1 inhibitor or pharmaceutically acceptable salt thereof in preparation of antitumor drugs for the first time based on the fact that the inventor finds that proliferation of tumor cells and tumor tissues can be inhibited by inhibiting expression and/or activity of UPK1A-AS1. The weight of a drug-administered animal is not remarkably influenced, and meanwhile, during drug administration, no drug treatment side effect is observed; and it is indicated that the UPK1A-AS1 inhibitor or the pharmaceutically acceptable salt thereof can inhibit the proliferation of tumor tissues, has no side effect, and can be used for preparing the antitumor drugs.

The present invention relates to an oral ulcer treating drug, which comprises 10 g of cortex phellodendri, and 4 g of honey. The production and taking method comprises that 10 g of cortex phellodendri, and 4 g of honey are weighed, 10 g of the cortex phellodendri is placed into an iron pot, a small amount of the honey is added, slight frying is performed with slow fire, and during the use, a proper amount of the obtained oral ulcer treating drug is applied on the affected area according to the ulcer area size 1-2 times a day, and generally the applying is performed 3-5 times so as to achieve the heal effect. With the oral ulcer treating drug of the present invention, the problems of the existing oral ulcer treating drug can be solved.

The invention belongs to the technical field of medicines, and relates to a pharmaceutical composition for treating a polycystic ovarian syndrome with obesity and a preparation method thereof. The pharmaceutical composition is carefully prepared from fructus ligustri lucidi, semen cuscutae, radix rehmanniae preparata, radix et caulis acanthopanacis senticosi, herba leonuri, all-grass of winkled marshweed, rhizoma pinelliae preparatum, roots of boerhaavia diffusa L., herba serissa serissoides (DC.) druce, rhizoma cyperi and licorice roots. According to the pharmaceutical composition, the effects of tonifying the liver and the kidney, activating blood circulation to dissipate blood stasis, eliminating dampness and phlegm and regulating menstruation and the blood are achieved, it is prompted through clinical observation experiment results that the pharmaceutical composition for treating the polycystic ovarian syndrome with the obesity can significantly relieve the clinical symptom, the internal secretion and hormonal level of a patient are adjusted, ovulation is facilitated, and new ideas and effective methods are provided for clinically treating the polycystic ovarian syndrome with the obesity.